Weighing the Risk of Drug Resistance With the Benefits of HIV Preexposure Prophylaxis

Robert M. Grant1,2,3 and Teri Liegler2

1Gladstone Institutes, 2University of California–San Francisco, and 3San Francisco AIDS Foundation, California

(See the major article by Lehman et al on pages 1211–8.)

Keywords. HIV; preexposure prophylaxis; antiretroviral; drug resistance.

The threat of drug resistance deserves careful attention from clinicians and public health officials advocating antiretroviral use as a way to control the human immunodeficiency virus (HIV) epidemic. Such antiretroviral use includes early treatment and preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP). Concerns about drug resistance were raised before rolling out widespread antiretroviral therapy in Africa, based on the assumption that adherence to therapy would be poor and drug resistance would become prevalent. Defying expectations, the benefits of antiretroviral therapy for improving health, averting death, and preventing transmission were subsequently proven to outweigh the risks of drug resistance, and adherence to therapy in African populations is often outstanding [1].

Fear of drug resistance is now posed as we consider rolling out PrEP. Daily oral PrEP using emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or TDF alone is safe and effective for preventing HIV acquisition [2–5] in sexually active adults. Adherence is essential for effectiveness [2, 6, 7]. Such regimens do not fully suppress systemic HIV infection, so starting PrEP in people already infected with HIV may lead to drug resistance [2–4]. Recommendations for PrEP emphasize the importance of HIV testing prior to starting or restarting PrEP.

In this issue of The Journal of Infectious Diseases, Lehman et al report new information about the risk of antiretroviral resistance from the Partners PrEP Study of men and women in Africa who are partnered with a person living with HIV [8]. (The usual term, “discordant couple,” obscures their commitment, courage, and cooperation.) The Partners PrEP Study is exceptional among randomized trials in that the levels of adherence were very high, with 71% of people randomly assigned to the active arm of the study having drug concentrations in plasma indicating consistent use [9]. Such higher adherence yielded higher PrEP effectiveness and makes this study ideal for evaluating the risk of drug resistance when PrEP fails to prevent HIV infection. The article confirms that drug resistance primarily occurs if systemic HIV infection is present when PrEP is started. This occurred in trials if people were enrolled during the HIV RNA–positive/HIV antibody–negative period of acute infection. Furthermore, drug resistance was primarily to FTC, which leaves multiple options for successful combination antiretroviral therapy. Importantly, the risk of drug resistance tended to be higher among people receiving FTC/TDF, compared with those receiving TDF alone (20% vs 5%; P = .1); this finding is consistent with nonhuman primate research on PrEP [10] and demonstrates how HIV develops resistance to the drug in the regimen with the lowest barrier to resistance. In HIV treatment, virological failure with resistance to only 1 drug in the multidrug regimen is the usual pattern, although resistance to other drugs appears later if a failing regimen is continued. This can occur with PrEP as well, as demonstrated by a trial participant who received FTC/TDF PrEP for 7 months before infection was detected by an oral fluid assay (seroconversion was detected after 1 month of PrEP, using a blood test conducted retrospectively) [4]. The lesson for PrEP drug development is that increasing the number of drugs in the regimen may increase, rather than decrease, the risk of drug resistance, especially if the added drug strongly selects for a single mutation having minimal effects on viral replication capacity.

However, the risk of FTC resistance must be weighed with any added efficacy afforded by adding FTC to TDF for PrEP. In the Partners PrEP Study, the relative...
failure still occurs among 5% of people per year [17]. The cumulative risk of drug resistance from PrEP services could be much lower than that associated with treating infections that would otherwise occur, as was predicted by mathematical models [18]; preventing HIV infection also prevents drug resistance.

Other benefits of PrEP are important. Coupled with regular monitoring, PrEP affords detection of breakthrough HIV-1 infection in a few weeks to months after infection, while diagnosis is frequently delayed for years among people who are not receiving prevention services. Access to PrEP and PEP may motivate people recently or frequently exposed to HIV to seek services. As such, population engagement motivated by PrEP access also creates opportunities for earlier diagnosis and treatment, preventing transmission and disease while minimizing viral reservoir size and enabling more timely services for partners, which should include PEP, PrEP, and early treatment.

Findings from trials may not necessarily apply to less controlled and monitored settings such as clinical practice. The Partners PrEP Study, like other trials, conducted monthly HIV testing, which minimized the duration of PrEP exposure after infection. Such frequent monitoring is not feasible in practice, and recommendations are to test for HIV every 3 months [19]. Nondaily use of PrEP or restarting PrEP after a lapse in use may occur in clinical practice, although this was not recommended in oral PrEP trials published so far. New information about the effectiveness and drug resistance risk associated with nondaily PrEP is expected from the ongoing ANRS-sponsored IPERGAY trial.

Lehman et al also provide evidence that more-sensitive assays for HIV drug resistance are warranted. Standard genotypic and phenotypic assays miss low-frequency mutations within a viral population that may affect virological response to therapy. Deep sequencing can detect such variants, although the clinical utility of this technology awaits clearly defined cutoff frequencies for individual drug resistance mutations. Lehman et al report that viral mutations were associated with the treatment arms when they occurred in >1% of the virus population, providing additional support for this being a clinically significant cutoff associated with drug selection, rather than naturally occurring polymorphism. Treatment responses were not evaluated, although they are expected to be excellent if therapy is guided by resistance testing.

There are ways to minimize the risk of drug resistance during PrEP use. Highly sensitive viral tests that detect RNA or antigen can rule out acute infection prior to starting PrEP. Point-of-care rapid RNA tests are available for research use, and feasible regulatory pathways leading to routine clinical use are urgently needed. If testing for HIV RNA or antigen is not available or not affordable, deferring PrEP in people with an acute viral syndrome will help, as the majority of acute HIV infections are symptomatic. Inviting PrEP users to inform providers about their stopping and starting of PrEP is important and provides an opportunity to arrange timely HIV testing. Home testing may make test access easier.

Some practices used to minimize the risk of HIV resistance are ill advised: attempting to restrict access to PrEP is expected to foster intermittent dosing, hoarding of medications, sharing among friends and partners, and other unsupervised use. Fomenting fear of drug resistance is also misguided if it distracts us from fear of HIV itself, by far the greater threat to human health.

**Notes**

**Financial support.** This work was supported by the National Institutes of Health and the Bill and Melinda Gates Foundation.

**Potential conflicts of interest.** Gilead Sciences donated study drug for R. M. G.’s research on PrEP, including the iPrEx trial, the iPrEx Open Label Extension, and the HPTN 067 ADAPT trial. T. L. certifies no potential conflicts of interest.

Both authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679–90.
2. Grant RM, Lama JR, Anderson PL, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587–99.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399–410.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423–34.
5. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083–90.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411–22.
7. Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir- emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Presented at: 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, Georgia, 2013.
8. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single or dual-agent pre-exposure prophylaxis. J Infect Dis 2015; 211:1211–8.
9. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr 2014; 66:340–8.
10. Garcia-Lerma JG, Cong ME, Mitchell J, et al. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci Transl Med 2010; 214ra4.
11. Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis 2014; 14:1055–64.
12. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 2012; 4151ra25.
13. Liegler T, Abdel-Mohsen M, Bentley LG, et al. HIV-1 resistance in the iPrEx pre-exposure prophylaxis trial. J Infect Dis 2014; 210:1217–27.
14. Grant RM, Anderson PL, McMahen V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis 2014; 14:820–9.
15. Patterson KB, Prince HA, Kraft E, et al. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med 2011; 3:112re4.
16. Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med 2014; 371:248–59.
17. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155–66.
18. Supervie V, Garcia-Lerma JG, Heneine W, Blower S. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A 2010; 107:12381–6.
19. Centers for Disease Control and Prevention (CDC). Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Atlanta, GA: CDC, 2014. http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf. Accessed 5 December 2014.